![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Response to 3 DAAs + RBV by Patient Characteristics: INTERFERON-FREE REGIMENS OF ABT-450/r,
ABT-267, ABT-333, AND RIBAVIRIN ACHIEVE HIGH SUSTAINED VIROLOGIC RESPONSE 12
WEEKS POST-TREATMENT (SVR12) RATES IN PATIENTS WITH CHRONIC HCV GENOTYPE 1
REGARDLESS OF RACE, ETHNICITY, OR OTHER BASELINE CHARACTERISTICS
|
|
|
Reported by Jules Levin
Digestive Disease Week (DDW) 2013
Orlando, FL, May 20, 2013
Maribel Rodriguez-Torres1, Frederick A. Nunes2, Daniel E. Cohen3, Wangang
Xie3, Christal Marincic3, Amit Khatri3, Tami Pilot-Matias3, Thomas Podsadecki3, and Barry Bernstein3
1: Fundación de Investigación de Diego, San Juan, PR, 2: Univeristy of
Pennsylvania Health System, Philadelphia, PA, 3: AbbVie Inc., North Chicago, IL
![DDW1.gif](../images/052113/052113-4/DDW1.gif)
![DDW2.gif](../images/052113/052113-4/DDW2.gif)
![DDW3.gif](../images/052113/052113-4/DDW3.gif)
![DDW4.gif](../images/052113/052113-4/DDW4.gif)
![DDW5.gif](../images/052113/052113-4/DDW5.gif)
![DDW6.gif](../images/052113/052113-4/DDW6.gif)
![DDW7.gif](../images/052113/052113-4/DDW7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|